Although the development of multimodality therapies including surgery, immunotherapy, and vascular endothelial growth factor (VEGF)-targeted therapy, prognosis of adult Xp11.2 RCC patients remains poor10, 11. This evidence concerns the gene VEGFA and renal cell carcinoma.